CASI Pharmaceuticals CASIF
OTC CASIF
$0.10 +0.00 (+0.05%)
As of: Oct 21, 2026 · 10:56 AM EDT

CASI Pharmaceuticals (CASIF) Short term Debt (2024 - 2026)

Updated

CASI Pharmaceuticals (CASIF) recorded Short term Debt of $19.78 million in Q2 2026, up 5.6% from $18.73 million a year earlier.

Analysis

CASI Pharmaceuticals (CASIF) Short term Debt (2024 - 2026) Analysis & Trends

At the end of FY2025, CASI Pharmaceuticals reported Short term Debt of $19.19 million, up 4.4% from FY2024.

  • Across earlier years, Short term Debt came in at $18.39 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 CASI Pharmaceuticals 1.86 Mn -18.97 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 19.78 Mn
Dec 31, 2025 19.19 Mn
Dec 31, 2024 18.39 Mn
API Access

CASI Pharmaceuticals Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=CASIF&period=max&api_key=YOUR_API_KEY